India Pharma Outlook Team | Wednesday, 14 October 2026
Today’s activity signals an accelerated AI obesity push alongside fresh funding and a major digital pathology acquisition.
Companies advanced an AI obesity push with multispecific protein therapies, completed a digital pathology buy that expands AI diagnostics, and secured funds that accelerate early-stage Indian biotech candidates.
These moves highlight strategic bets on artificial intelligence from late-stage metabolic programs through digital tools to preclinical discovery.
Industry players chase better options beyond existing weight-loss drugs, stronger diagnostic platforms, and validated leads for hard-to-treat conditions.
The concentrated activity on one day underscores how AI now drives partnerships, acquisitions, and public support in equal measure.
Danish obesity-drug developer Zealand Pharma partnered with US biotechnology firm Generate Biomedicines to create AI-designed multispecific protein therapies for obesity and other metabolic diseases.
The collaboration carries a total potential value of nearly USD 1.2 billion. Generate receives USD 30 million upfront and up to USD 35 million in early preclinical milestones. Generate leads research through candidate selection, while Zealand handles clinical development, regulatory submissions, and worldwide commercialization.
The companies focus on medicines that act on more than one biological target at a time. These multispecific approaches aim to address several disease pathways linked to obesity within a single treatment.
The deal arrives as drugmakers race to develop new obesity treatments beyond the blockbuster GLP-1 weight-loss drugs from Novo Nordisk and Eli Lilly. Success of those medicines has already fuelled broader investment in approaches that improve effectiveness, convenience, or side-effect profiles.
Generate, a Flagship Pioneering-backed company that recently went public, applies its AI-driven technology to design protein-based medicines. Zealand, traditionally focused on peptide-based therapies, continues to expand its metabolic pipeline through this AI-enabled route.
Also Read: India's Role in Shaping the Future of Oncology and Immunology
Agilent Technologies agreed to acquire pathology software maker Proscia for USD 240 million in cash, plus up to USD 30 million tied to future performance targets.
Privately held Proscia develops software that converts pathology slides into digital images that laboratories can store, review, and analyze with artificial intelligence tools.
The acquisition strengthens Agilent’s pathology business and expands its presence in digital and AI-enabled diagnostics. It also gives Agilent access to a high-growth software segment that generated more than USD 18 million in revenue over the past 12 months.
The companies have worked together since 2022 under a multi-year distribution agreement that already combines Agilent’s pathology products with Proscia’s software. Agilent expects the deal to close early in fiscal 2027.
Bengaluru-based drug discovery startup Peptris Technologies secured Rs 86 crore under the Research, Development and Innovation (RDI) Fund of the Technology Development Board. The support arrives as optionally convertible debt.
These funds advance the VIGOR project, which moves four AI-discovered candidates from Technology Readiness Level (TRL) 4 to TRL 6 over three years. The total project cost stands at Rs 172 crore. The candidates include:
Peptris will conduct preclinical development, validation, and investigational new drug-enabling studies. The company will also engage global contract research organizations to support the work. The RDI Fund backs technology-intensive programs that bridge the gap between innovation and clinical development.
Together, the AI obesity push, the digital pathology buy, and the RDI funds illustrate how capital and technical capability flow into AI-powered approaches at every stage of the pharma value chain, from late-stage metabolic innovation and diagnostics to early-stage Indian biotech discovery.
.jpg)
